ZA202103976B - Immunogenic compositions for treatment of hepatitis b - Google Patents

Immunogenic compositions for treatment of hepatitis b

Info

Publication number
ZA202103976B
ZA202103976B ZA2021/03976A ZA202103976A ZA202103976B ZA 202103976 B ZA202103976 B ZA 202103976B ZA 2021/03976 A ZA2021/03976 A ZA 2021/03976A ZA 202103976 A ZA202103976 A ZA 202103976A ZA 202103976 B ZA202103976 B ZA 202103976B
Authority
ZA
South Africa
Prior art keywords
hepatitis
treatment
immunogenic compositions
immunogenic
compositions
Prior art date
Application number
ZA2021/03976A
Other languages
English (en)
Inventor
Evander Anderson David
Ahmed Tanvir
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of ZA202103976B publication Critical patent/ZA202103976B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2021/03976A 2018-11-13 2021-06-09 Immunogenic compositions for treatment of hepatitis b ZA202103976B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862760439P 2018-11-13 2018-11-13
PCT/IB2019/001230 WO2020099927A1 (en) 2018-11-13 2019-11-13 Immunogenic compositions for treatment of hepatitis b

Publications (1)

Publication Number Publication Date
ZA202103976B true ZA202103976B (en) 2023-09-27

Family

ID=70731781

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/03976A ZA202103976B (en) 2018-11-13 2021-06-09 Immunogenic compositions for treatment of hepatitis b

Country Status (10)

Country Link
US (2) US12128100B2 (https=)
EP (1) EP3880244A4 (https=)
JP (2) JP2022513001A (https=)
KR (1) KR102943479B1 (https=)
CN (2) CN118987191A (https=)
BR (1) BR112021009234A2 (https=)
IL (2) IL314712A (https=)
MX (1) MX2021005588A (https=)
WO (1) WO2020099927A1 (https=)
ZA (1) ZA202103976B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020099927A1 (en) 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b
US20240123060A1 (en) * 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b
AU2024313135A1 (en) 2023-06-23 2026-01-22 Brii Biosciences, Inc. Assessment and treatment of chronic hepatitis b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242812A (en) 1989-02-07 1993-09-07 Bio-Technology General Corp. Method for production and purification of hepatitis B vaccine
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
CN1305527C (zh) 2003-11-21 2007-03-21 薛平 乙型肝炎治疗疫苗及其制备方法
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Hbv 백신 및 그의 제조 방법
CN102949717A (zh) 2012-07-06 2013-03-06 中国疾病预防控制中心病毒病预防控制所 一种含poly I:C佐剂的新型乙肝疫苗制剂
CN104043120B (zh) 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
WO2018166298A1 (en) 2017-03-13 2018-09-20 Fudan University Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
WO2020099927A1 (en) * 2018-11-13 2020-05-22 Variation Biotechnologies Inc. Immunogenic compositions for treatment of hepatitis b
US20240123060A1 (en) 2019-06-21 2024-04-18 Variation Biotechnologies Inc. Improved therapeutic composition comprising hepatitis b antigen having s, pre-s1 and pre-s2 protein, aluminium phosphate and interferon-alpha and use thereof for treatment of hepatitis b

Also Published As

Publication number Publication date
US20250269013A1 (en) 2025-08-28
EP3880244A1 (en) 2021-09-22
KR102943479B1 (ko) 2026-03-27
CA3119581A1 (en) 2020-05-22
KR20210151047A (ko) 2021-12-13
BR112021009234A2 (pt) 2021-09-08
US12128100B2 (en) 2024-10-29
IL283039B1 (en) 2024-09-01
JP2024174990A (ja) 2024-12-17
CN113423423A (zh) 2021-09-21
MX2021005588A (es) 2021-08-11
IL283039A (en) 2021-06-30
WO2020099927A1 (en) 2020-05-22
EP3880244A4 (en) 2022-08-17
US20230079703A1 (en) 2023-03-16
IL283039B2 (en) 2025-01-01
IL314712A (en) 2024-10-01
JP2022513001A (ja) 2022-02-07
CN113423423B (zh) 2024-08-13
CN118987191A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
ZA201708236B (en) Methods and compositions for rna-guided treatment of hiv infection
IL281277A (en) Preparations and methods for treating viral infections
IL281220A (en) Process for preparing vaccine compositions
IL257384A (en) Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus
GB201720163D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of hepatitis B
ZA202006610B (en) Compositions for the treatment of skin conditions
IL280769B1 (en) Novel sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
ZA202007055B (en) Compositions for the treatment of skin conditions
SG11201802983TA (en) Therapeutic compositions for treatment of human immunodeficiency virus
EP3280422A4 (en) Compositions and methods for the treatment of hbv infection
IL269590A (en) Methods and compositions for reducing immunogenicity
LT3573620T (lt) Kompozicijos, skirtos hipertenzijos gydymui
ZA201907096B (en) Methods of using drift reduction adjuvant compositions
ZA202103976B (en) Immunogenic compositions for treatment of hepatitis b
SG11201805729SA (en) Therapeutic compositions and methods for treating hepatitis b
GB201802339D0 (en) Immunogenic composition
SG11202009147UA (en) Vaccine compositions
IL291559A (en) Immunogenic preparations
ZA202006591B (en) Compositions for the treatment of hypertension
SG11202103389WA (en) Immunogenic compositions
ZA201903572B (en) Compositions and methods for the treatment of oral infectious diseases
PL3810625T3 (pl) Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b
IL263336B (en) Compounds for the treatment of symphysiolysis
GB201803692D0 (en) Immunogenic composition
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies